Search

Your search keyword '"M. Blüher"' showing total 793 results
Start Over Author "M. Blüher"
793 results on '"M. Blüher"'

1. Augmented manipulation ability in humans with six-fingered hands

Author

C. Mehring, M. Akselrod, L. Bashford, M. Mace, H. Choi, M. Blüher, A.-S. Buschhoff, T. Pistohl, R. Salomon, A. Cheah, O. Blanke, A. Serino, and E. Burdet

Subjects
Science
Abstract

Can the human brain successfully control additional body parts beyond the ones we normally possess? Here, the authors study two polydactyly individuals (with an additional finger on each hand) and show that they can carry out more complex movements, performing with only one hand tasks normally requiring two.

Published
2019
Full Text
View/download PDF

2. Up-regulated autophagy: as a protective factor in adipose tissue of WOKW rats with metabolic syndrome

Author

J. Kosacka, M. Nowicki, S. Paeschke, P. Baum, M. Blüher, and N. Klöting

Subjects
Autophagy, Adipose tissue, LY294002 inhibitor, Metabolic syndrome, WOKW rats, Nutritional diseases. Deficiency diseases, RC620-627
Abstract

Abstract Background Wistar Ottawa Karlsburg W (RT1u) rats (WOKW) are a model of the metabolic syndrome (MetS). Adipose tissue (AT) and peripheral nerves of WOKW rats exhibit up-regulated autophagy and inflammation corresponding with decreased apoptosis rate. The aim of this study was to characterize AT in WOKW rats in relation to autophagic activity. Methods mRNA and protein expression of adiponectin, pro-inflammatory and pro-apoptotic markers including MCP1, TNFα, cleaved caspase-3 and RNF157, a new candidate gene regulated through autophagy, were analyzed in adipocytes isolated from visceral and subcutaneous AT of 5-month old WOKW rats with MetS and LEW.1W controls in response to pharmacological inhibition of autophagy. Immunohistochemistry was performed to detect adiponectin and RNF157 protein in cultured adipocytes. Results Inhibition of autophagy by LY294002 was associated with a fourfold up-regulation of adiponectin expression and a decrease of RNF157 protein and pro-inflammatory markers—MCP-1 and TNFα predominantly in visceral adipocytes of obese WOKW rats compared to LEW.1W rats. Moreover, inhibition of autophagic activity correlates with an activation of cleaved caspase-3 apoptotic signaling pathway. Conclusions Up-regulated autophagy in obese WOKW rats contributes to the regulation of visceral AT function and involves an altered balance between pro-inflammatory and protective adipokine expression. Our data suggest that activation of AT autophagy protects against adipocyte apoptosis at least under conditions of obesity related MetS in WOKW rats.

Published
2018
Full Text
View/download PDF

3. Obesogenic memory can confer long-term increases in adipose tissue but not liver inflammation and insulin resistance after weight loss

Author

J. Schmitz, N. Evers, M. Awazawa, H.T. Nicholls, H.S. Brönneke, A. Dietrich, J. Mauer, M. Blüher, and J.C. Brüning

Subjects
Internal medicine, RC31-1245
Abstract

Objective: Obesity represents a major risk factor for the development of type 2 diabetes mellitus, atherosclerosis and certain cancer entities. Treatment of obesity is hindered by the long-term maintenance of initially reduced body weight, and it remains unclear whether all pathologies associated with obesity are fully reversible even upon successfully maintained weight loss. Methods: We compared high fat diet-fed, weight reduced and lean mice in terms of body weight development, adipose tissue and liver insulin sensitivity as well as inflammatory gene expression. Moreover, we assessed similar parameters in a human cohort before and after bariatric surgery. Results: Compared to lean animals, mice that demonstrated successful weight reduction showed increased weight gain following exposure to ad libitum control diet. However, pair-feeding weight-reduced mice with lean controls efficiently stabilized body weight, indicating that hyperphagia was the predominant cause for the observed weight regain. Additionally, whereas glucose tolerance improved rapidly after weight loss, systemic insulin resistance was retained and ameliorated only upon prolonged pair-feeding. Weight loss enhanced insulin action and resolved pro-inflammatory gene expression exclusively in the liver, whereas visceral adipose tissue displayed no significant improvement of metabolic and inflammatory parameters compared to obese mice. Similarly, bariatric surgery in humans (n = 55) resulted in massive weight reduction, improved hepatic inflammation and systemic glucose homeostasis, while adipose tissue inflammation remained unaffected and adipocyte-autonomous insulin action only exhibit minor improvements in a subgroup of patients (42%). Conclusions: These results demonstrate that although sustained weight loss improves systemic glucose homeostasis, primarily through improved inflammation and insulin action in liver, a remarkable obesogenic memory can confer long-term increases in adipose tissue inflammation and insulin resistance in mice as well as in a significant subpopulation of obese patients. Keywords: Obesity, Weight loss, Weight regain, Insulin resistance, Metabolic inflammation

Published
2016
Full Text
View/download PDF

7. Sex-dimorphic genetic effects and novel loci for fasting glucose and insulin variability

Author

Tove Fall, Anubha Mahajan, Dmitry Shungin, B. Balkau, Gerjan Navis, A. Metspalu, Anneli Pouta, Andrew A. Hicks, Ilja M. Nolte, Ian Ford, Aroon D. Hingorani, Stefan R Bornstein, Anuj Goel, Rona J. Strawbridge, Niek Verweij, Sarah H. Wild, Patricia B. Munroe, T.B. Harris, Jaana Lindström, Johnson Pcd., Nita G. Forouhi, Pierre Meneton, Patricia A. Peyser, Sarin A-P., Andrea Ganna, Timothy M. Frayling, Patrik K. E. Magnusson, Joanne M. Meyer, Yongmei Liu, Jeanette M. Stafford, Christian Herder, L Zudina, Maria G. Stathopoulou, May E. Montasser, Nicholas D. Hastie, Inês Barroso, Schwarz Peh., James B. Meigs, Perttu Salo, George Davey Smith, Gonneke Willemsen, Christopher J. Groves, Erik P A Van Iperen, M. A. Province, Veikko Salomaa, Naveed Sattar, Serena Sanna, Maria Dimitriou, Joop Jukema, Ulrika Krus, Albert V. Smith, Markku Laakso, James F. Wilson, George Nicholson, Loic Yengo, Tatijana Zemunik, Per Eriksson, Harold Snieder, Peter P. Pramstaller, Claudia Langenberg, R. Rauramaa, Alan R. Shuldiner, Pau Navarro, Veronique Vitart, Ross M. Fraser, Aaron Isaacs, C. Lecoeur, Jesper R. Gådin, Jackie F. Price, Letizia Marullo, L.F. Bielak, Sirkka Keinänen-Kiukaanniemi, Amélie Bonnefond, Michael Stumvoll, Alessia Faggian, Anke Tönjes, Tomohiro Tanaka, Wieland Kiess, Harry Campbell, Josée Dupuis, David Altshuler, João Fadista, Winfried März, G K Hovingh, Thomas Illig, Toby Johnson, H Grallert, Kari Stefansson, Reedik Mägi, Palmer Cna., de Geus Ejcn., Martina Müller-Nurasyid, Karen Kapur, Philippe Froguel, Dorret I. Boomsma, Anders Franco-Cereceda, Marcus E. Kleber, Boehnke M, Olga D. Carlson, Ozren Polasek, Andrew P. Morris, Alex S. F. Doney, Najaf Amin, Sara M. Willems, Vilmundur Gudnason, Jose C. Florez, Jeffery R. O'Connell, Nancy L. Pedersen, T. Saaristo, Wolffenbuttel Bhr., M. I. J. Uusitupa, Longda Jiang, Iva Miljkovic, James S. Pankow, Caroline Hayward, Hugh Watkins, Vasiliki Lagou, Johanna Kuusisto, Jaakko Tuomilehto, Alan F. Wright, Josephine M. Egan, Perry Jrb., C M van Duijn, Valeriya Lyssenko, Leif Groop, Stefania Bandinelli, Nigel W. Rayner, Tõnu Esko, Stela McLachlan, Momoko Horikoshi, Eric Boerwinkle, Rick Jansen, Richard N. Bergman, Gudmar Thorleifsson, Lyle J. Palmer, Vilmantas Giedraitis, Peter Kovacs, Nicholas J. Wareham, Luigi Ferrucci, N J Timpson, D Rybin, Anne U. Jackson, Tiinamaija Tuomi, Gonçalo R. Abecasis, Harst Pvd., Meena Kumari, Albert Hofman, Chiara Scapoli, Evelin Mihailov, Josine L. Min, Anders Hamsten, Hottenga J-J., Loos Rjf., Lars Lind, Ulf de Faire, Jaakko Kaprio, Guo Li, Beate St Pourcain, C Gieger, Amanda J. Bennett, Anna Ulrich, Nabila Bouatia-Naji, Satu Männistö, Antigone S. Dimas, Jarvelin M-R., Günther Silbernagel, F Karpe, A. Körner, David S. Siscovick, M Blüher, Rebecca J. Webster, Erik Ingelsson, Susan Campbell, Mika Kivimäki, Laura J. Rasmussen-Torvik, Heikki A. Koistinen, Sophie Visvikis-Siest, Bernhard O. Boehm, Inga Prokopenko, Ping An, Emmanouil T. Dermitzakis, Cecilia M. Lindgren, Kardia Slr., Richa Saxena, Igor Rudan, Richard M. Watanabe, Jian'an Luan, Marika Kaakinen, Shin S-Y., George Dedoussis, Panagiotis Deloukas, Mark I. McCarthy, Barbara Thorand, B.W.J.H. Penninx, Peter Vollenweider, Paul W. Franks, Leena Kinnunen, Markus Perola, Yvonne Boettcher, Timo A. Lakka, Nicole Soranzo, Stavroula Kanoni, Bakker Sjl., Winkelmann Br, The Wellcome Trust Centre for Human Genetics [Oxford], University of Oxford [Oxford], Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), Institute of Genomics [Tartu, Estonia], University of Tartu, Vrije Universiteit Amsterdam [Amsterdam] (VU), Vrije Universiteit Medical Centre (VUMC), Helmholtz-Zentrum München (HZM), University of Cambridge [UK] (CAM), Metabolic functional (epi)genomics and molecular mechanisms involved in type 2 diabetes and related diseases - UMR 8199 - UMR 1283 (GI3M), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre National de la Recherche Scientifique (CNRS), Paris-Centre de Recherche Cardiovasculaire (PARCC (UMR_S 970/ U970)), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Università degli Studi di Ferrara (UniFE), Boston University [Boston] (BU), VU University Medical Center [Amsterdam], University of Bristol [Bristol], Biomedical Sciences Research Centre Alexander Fleming [Vari, Greece] (BSRC), Imperial College London, Karolinska Institutet [Stockholm], Institute for Molecular Bioscience, University of Queensland [Brisbane], Statens Serum Institut [Copenhagen], Interactions Gène-Environnement en Physiopathologie Cardio-Vasculaire (IGE-PCV), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Erasmus University Medical Center [Rotterdam] (Erasmus MC), Cardiovascular Research Institute Maastricht (CARIM), Maastricht University [Maastricht], MRC Institute of Genetics and Molecular Medicine [Edinburgh] (IGMM), University of Edinburgh-Medical Research Council, National Institute on Aging [Baltimore, MD, USA] (NIH), University of Michigan [Ann Arbor], University of Michigan System, University of Maryland School of Medicine, University of Maryland System, The University of Western Australia (UWA), Broad Institute of MIT and Harvard (BROAD INSTITUTE), Harvard Medical School [Boston] (HMS)-Massachusetts Institute of Technology (MIT)-Massachusetts General Hospital [Boston], Massachusetts General Hospital [Boston], Harvard Medical School [Boston] (HMS), Wake Forest University, National Institute for Health and Welfare [Helsinki], The Wellcome Trust Sanger Institute [Cambridge], University of Iceland [Reykjavik], University of Washington [Seattle], University of Groningen [Groningen], University of Glasgow, William Harvey Research Institute, Barts and the London Medical School, Université de Lausanne (UNIL), deCODE genetics [Reykjavik], Northwestern University Feinberg School of Medicine, Uppsala Universitet [Uppsala], University of Edinburgh, Medical Faculty [Mannheim], University of Graz, Ludwig-Maximilians-Universität München (LMU), Johannes Gutenberg - Universität Mainz (JGU), Institute for Molecular Medicine Finland [Helsinki] (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki-University of Helsinki, Umeå University, Skane University Hospital [Malmo], Lund University [Lund], RIKEN Center for Integrative Medical Sciences [Yokohama] (RIKEN IMS), RIKEN - Institute of Physical and Chemical Research [Japon] (RIKEN), Washington University School of Medicine in St. Louis, Washington University in Saint Louis (WUSTL), Istituto di Ricerca Genetica e Biomedica (IRGB), Consiglio Nazionale delle Ricerche [Roma] (CNR), University Medical Center Groningen [Groningen] (UMCG), Universität Leipzig [Leipzig], Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM), University of Split, Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA), University of Eastern Finland, Harokopio University of Athens, European Academy Bozen/Bolzano (EURAC), University of Kuopio, German Center for Diabetes Research - Deutsches Zentrum für Diabetesforschung [Neuherberg] (DZD), University of Pittsburgh (PITT), Pennsylvania Commonwealth System of Higher Education (PCSHE), Ninewells Hospital and Medical School [Dundee], University College of London [London] (UCL), University of Essex, Heinrich Heine Universität Düsseldorf = Heinrich Heine University [Düsseldorf], University of Helsinki, Leiden University Medical Center (LUMC), Institute of Cardiovascular and Medical Sciences [Glasgow], University of Oulu, The University of Texas Health Science Center at Houston (UTHealth), University of Minnesota Medical School, University of Minnesota System, Keck School of Medicine [Los Angeles], University of Southern California (USC), Amsterdam UMC, University Hospital Carl Gustav Carus [Dresden, Germany], Technische Universität Dresden = Dresden University of Technology (TU Dresden), Lee Kong Chian School of Medicine, Nanyang Technological University (NTU), Universität Heidelberg [Heidelberg], King Abdulaziz University, Pirkanmaa Hospital District, Tampere University Hospital, Cedars-Sinai Medical Center, Danube University Krems, Harvard School of Public Health, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Institute of Epidemiology [Neuherberg] (EPI), German Research Center for Environmental Health - Helmholtz Center München (GmbH), Hannover Medical School [Hannover] (MHH), Universität zu Lübeck [Lübeck], University of Exeter, Regeneron Pharmaceuticals [Tarrytown], University of Adelaide, Centre de Recherche des Cordeliers (CRC (UMR_S 872)), Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), National Institute on Aging [Bethesda, USA] (NIA), National Institutes of Health [Bethesda] (NIH), Icahn School of Medicine at Mount Sinai [New York] (MSSM), Harvard T.H. Chan School of Public Health, John Radcliffe Hospital [Oxford University Hospital], Centre Hospitalier Universitaire Vaudois [Lausanne] (CHUV), Université de Genève (UNIGE), Big Data Institute, University of Surrey (UNIS), University of Bergen (UiB), Stanford School of Medicine [Stanford], Stanford Medicine, Stanford University-Stanford University, Stanford Cardiovascular Institute, University of Liverpool, University of Manchester [Manchester], Institute of Biochemistry and Genetics of Ufa Scientific Centre, Russian Academy of Sciences [Moscow] (RAS), Experimental Vascular Medicine, Vascular Medicine, ACS - Atherosclerosis & ischemic syndromes, SIEST, Sofia, PreciDIAB Institute, the holistic approach of personal diabets care - - PreciDIAB2018 - ANR-18-IBHU-0001 - IBHU - VALID, Understanding the dynamic determinants of glucose homeostasis and social capability to promote Healthy and active aging - DYNAHEALTH - - H20202015-04-01 - 2019-03-31 - 633595 - VALID, Beyond the Genetics of Addiction - ADDICTION - - EC:FP7:ERC2011-12-01 - 2017-05-31 - 284167 - VALID, Rise of scientific excellence and collaboration for implementing personalised medicine in Estonia - ePerMed - - H20202016-01-01 - 2018-12-31 - 692145 - VALID, University of Oxford, Helmholtz Zentrum München = German Research Center for Environmental Health, Metabolic functional (epi)genomics and molecular mechanisms involved in type 2 diabetes and related diseases - UMR 8199 - UMR 1283 (EGENODIA (GI3M)), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Università degli Studi di Ferrara = University of Ferrara (UniFE), Université de Lausanne = University of Lausanne (UNIL), Karl-Franzens-Universität Graz, Johannes Gutenberg - Universität Mainz = Johannes Gutenberg University (JGU), Helsingin yliopisto = Helsingfors universitet = University of Helsinki-Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Amsterdam UMC - Amsterdam University Medical Center, Nanyang Technological University [Singapour], Universität zu Lübeck = University of Lübeck [Lübeck], Laboratoire d'Informatique Médicale et Ingénierie des Connaissances en e-Santé (LIMICS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Sorbonne Paris Nord, Université de Genève = University of Geneva (UNIGE), ANR-18-IBHU-0001,PreciDIAB,PreciDIAB Institute, the holistic approach of personal diabets care(2018), European Project: 633595,H2020,H2020-PHC-2014-two-stage,DYNAHEALTH(2015), European Project: 284167,EC:FP7:ERC,ERC-2011-StG_20101124,ADDICTION(2011), European Project: 692145,H2020,H2020-TWINN-2015,ePerMed(2016), Biological Psychology, APH - Health Behaviors & Chronic Diseases, APH - Personalized Medicine, Functional Genomics, APH - Mental Health, Sociology and Social Gerontology, APH - Methodology, Hottenga, Jouke- Jan [0000-0002-5668-2368], Bouatia-Naji, Nabila [0000-0001-5424-2134], Jansen, Rick [0000-0002-3333-6737], Min, Josine L. [0000-0003-4456-9824], Faggian, Alessia [0000-0002-3799-9722], Bonnefond, Amélie [0000-0001-9976-3005], Isaacs, Aaron [0000-0001-5037-4834], Willems, Sara M. [0000-0002-6803-3007], Navarro, Pau [0000-0001-5576-8584], Jackson, Anne U. [0000-0002-9672-2547], Bielak, Lawrence F. [0000-0002-3443-8030], Saxena, Richa [0000-0003-2233-1065], Smith, Albert V. [0000-0003-1942-5845], Verweij, Niek [0000-0002-4303-7685], Goel, Anuj [0000-0003-2307-4021], Johnson, Paul C. D. [0000-0001-6663-7520], Strawbridge, Rona J. [0000-0001-8506-3585], Fall, Tove [0000-0003-2071-5866], Fraser, Ross M. [0000-0003-0488-2592], Kanoni, Stavroula [0000-0002-1691-9615], Giedraitis, Vilmantas [0000-0003-3423-2021], Kleber, Marcus E. [0000-0003-0663-7275], Müller-Nurasyid, Martina [0000-0003-3793-5910], Luan, Jian’an [0000-0003-3137-6337], Sanna, Serena [0000-0002-3768-1749], Nolte, Ilja M. [0000-0001-5047-4077], Zemunik, Tatijana [0000-0001-8120-2891], Kovacs, Peter [0000-0002-0290-5423], Wild, Sarah H. [0000-0001-7824-2569], McLachlan, Stela [0000-0003-0480-6143], Egan, Josephine [0000-0002-8945-0053], Hicks, Andrew A. [0000-0001-6320-0411], Thorand, Barbara [0000-0002-8416-6440], Hingorani, Aroon [0000-0001-8365-0081], Kivimaki, Mika [0000-0002-4699-5627], Koistinen, Heikki A. [0000-0001-7870-070X], Bakker, Stephan J. L. [0000-0003-3356-6791], Palmer, Colin N. A. [0000-0002-6415-6560], Jukema, J. Wouter [0000-0002-3246-8359], Sattar, Naveed [0000-0002-1604-2593], Snieder, Harold [0000-0003-1949-2298], Magnusson, Patrik K. [0000-0002-7315-7899], Blüher, Matthias [0000-0003-0208-2065], Wolffenbuttel, Bruce H. R. [0000-0001-9262-6921], Abecasis, Goncalo R. [0000-0003-1509-1825], Meigs, James B. [0000-0002-2439-2657], Wilson, James F. [0000-0001-5751-9178], Schwarz, Peter E. H. [0000-0001-6317-7880], Boehm, Bernhard O. [0000-0002-2706-7710], Metspalu, Andres [0000-0002-3718-796X], Deloukas, Panos [0000-0001-9251-070X], Körner, Antje [0000-0001-6001-0356], Wareham, Nicholas J. [0000-0003-1422-2993], Langenberg, Claudia [0000-0002-5017-7344], Männistö, Satu [0000-0002-8668-3046], Franks, Paul W. [0000-0002-0520-7604], Hayward, Caroline [0000-0002-9405-9550], Vitart, Veronique [0000-0002-4991-3797], Kaprio, Jaakko [0000-0002-3716-2455], Visvikis-Siest, Sophie [0000-0001-8104-8425], Altshuler, David [0000-0002-7250-4107], Rudan, Igor [0000-0001-6993-6884], van Duijn, Cornelia M. [0000-0002-2374-9204], Pramstaller, Peter P. [0000-0002-9831-8302], Boehnke, Michael [0000-0002-6442-7754], Frayling, Timothy M. [0000-0001-8362-2603], Peyser, Patricia A. [0000-0002-9717-8459], Harst, Pim van der [0000-0002-2713-686X], Smith, George Davey [0000-0002-1407-8314], Forouhi, Nita G. [0000-0002-5041-248X], Loos, Ruth J. F. [0000-0002-8532-5087], Salomaa, Veikko [0000-0001-7563-5324], Soranzo, Nicole [0000-0003-1095-3852], Boomsma, Dorret I. [0000-0002-7099-7972], Groop, Leif [0000-0002-0187-3263], Tuomi, Tiinamaija [0000-0002-8306-6202], Munroe, Patricia B. [0000-0002-4176-2947], Gudnason, Vilmundur [0000-0001-5696-0084], Lecoeur, Cecile [0000-0003-0075-6417], Jarvelin, Marjo-Riitta [0000-0002-2149-0630], Stefansson, Kari [0000-0003-1676-864X], Dermitzakis, Emmanouil T. [0000-0002-9302-6490], Lindgren, Cecilia M. [0000-0002-4903-9374], Froguel, Philippe [0000-0003-2972-0784], Kaakinen, Marika A. [0000-0002-9228-0462], Watanabe, Richard M. [0000-0003-1015-0531], Ingelsson, Erik [0000-0003-2256-6972], Dupuis, Josée [0000-0003-2871-3603], Barroso, Inês [0000-0001-5800-4520], Apollo - University of Cambridge Repository, Epidemiology, University Hospital Mannheim | Universitätsmedizin Mannheim, National Research Council of Italy | Consiglio Nazionale delle Ricerche (CNR), Universität Leipzig, Universiteit Leiden, Universität Heidelberg [Heidelberg] = Heidelberg University, Karl-Franzens-Universität [Graz, Autriche], Psychiatry, Amsterdam Neuroscience - Complex Trait Genetics, Amsterdam Neuroscience - Mood, Anxiety, Psychosis, Stress & Sleep, General practice, APH - Digital Health, Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI), Life Course Epidemiology (LCE), Lifestyle Medicine (LM), Groningen Institute for Organ Transplantation (GIOT), Groningen Kidney Center (GKC), Center for Liver, Digestive and Metabolic Diseases (CLDM), Value, Affordability and Sustainability (VALUE), Cardiovascular Centre (CVC), Hottenga, Jouke-Jan [0000-0002-5668-2368], Min, Josine L [0000-0003-4456-9824], Willems, Sara M [0000-0002-6803-3007], Jackson, Anne U [0000-0002-9672-2547], Bielak, Lawrence F [0000-0002-3443-8030], Smith, Albert V [0000-0003-1942-5845], Johnson, Paul CD [0000-0001-6663-7520], Strawbridge, Rona J [0000-0001-8506-3585], Fraser, Ross M [0000-0003-0488-2592], Kleber, Marcus E [0000-0003-0663-7275], Luan, Jian'an [0000-0003-3137-6337], Nolte, Ilja M [0000-0001-5047-4077], Wild, Sarah H [0000-0001-7824-2569], Hicks, Andrew A [0000-0001-6320-0411], Koistinen, Heikki A [0000-0001-7870-070X], Bakker, Stephan JL [0000-0003-3356-6791], Palmer, Colin NA [0000-0002-6415-6560], Jukema, J Wouter [0000-0002-3246-8359], Magnusson, Patrik K [0000-0002-7315-7899], Wolffenbuttel, Bruce HR [0000-0001-9262-6921], Abecasis, Goncalo R [0000-0003-1509-1825], Meigs, James B [0000-0002-2439-2657], Wilson, James F [0000-0001-5751-9178], Schwarz, Peter EH [0000-0001-6317-7880], Boehm, Bernhard O [0000-0002-2706-7710], Wareham, Nicholas J [0000-0003-1422-2993], Franks, Paul W [0000-0002-0520-7604], van Duijn, Cornelia M [0000-0002-2374-9204], Pramstaller, Peter P [0000-0002-9831-8302], Frayling, Timothy M [0000-0001-8362-2603], Peyser, Patricia A [0000-0002-9717-8459], Forouhi, Nita G [0000-0002-5041-248X], Loos, Ruth JF [0000-0002-8532-5087], Boomsma, Dorret I [0000-0002-7099-7972], Munroe, Patricia B [0000-0002-4176-2947], Dermitzakis, Emmanouil T [0000-0002-9302-6490], Lindgren, Cecilia M [0000-0002-4903-9374], Kaakinen, Marika A [0000-0002-9228-0462], Watanabe, Richard M [0000-0003-1015-0531], Tampere University, Tays Research Services, Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC), Fysiologie, RS: FHML MaCSBio, and RS: Carim - B01 Blood proteins & engineering

Subjects
Male, Anorexia Nervosa, medicine.medical_treatment, 45/43, Insulin Resistance/genetics, SUSCEPTIBILITY, Quantitative trait, Impaired glucose tolerance, 0302 clinical medicine, Architecture, LS2_1, IMPUTATION, Insulin, ComputingMilieux_MISCELLANEOUS, Fasting, Publisher Correction, 3. Good health, [SDV] Life Sciences [q-bio], Kruppel-Like Transcription Factors/blood, Endokrinologi och diabetes, Science & Technology - Other Topics, Adult, Blood Glucose, European Continental Ancestry Group, Female, Gene Expression, Genetic Loci, Genome-Wide Association Study, Glucose Intolerance, Humans, Insulin Receptor Substrate Proteins, Insulin Resistance, Kruppel-Like Transcription Factors, Middle Aged, Phenotype, Sex Characteristics, Sex Factors, Waist-Hip Ratio, Sex characteristics, medicine.medical_specialty, Science, 631/208/205/2138, Endocrinology and Diabetes, General Biochemistry, Genetics and Molecular Biology, White People, Gender-differences, 03 medical and health sciences, SDG 3 - Good Health and Well-being, 692/53/2421, GLYCEMIC TRAITS, GENOME-WIDE ASSOCIATION, Glycemic, GENDER-DIFFERENCES, Science & Technology, IDENTIFICATION, 692/699/2743/2815, Blood Glucose/metabolism, Diagnostic markers, medicine.disease, Anorexia Nervosa/blood, 030104 developmental biology, Endocrinology, Glucose, Insulin/blood, Anorexia Nervosa/ethnology, Anorexia Nervosa/genetics, Anorexia Nervosa/physiopathology, Fasting/blood, Glucose Intolerance/blood, Glucose Intolerance/ethnology, Glucose Intolerance/genetics, Glucose Intolerance/physiopathology, Insulin Receptor Substrate Proteins/blood, Insulin Receptor Substrate Proteins/genetics, Kruppel-Like Transcription Factors/genetics, 0301 basic medicine, Identification, [SDV]Life Sciences [q-bio], General Physics and Astronomy, Genome-wide association studies, Waist–hip ratio, LS4_5, RISK, ARCHITECTURE, Multidisciplinary, article, Type 2 diabetes, Multidisciplinary Sciences, MENDELIAN RANDOMIZATION, Pre-diabetes, Medical Genetics, Risk, PATHOPHYSIOLOGY, 030209 endocrinology & metabolism, 3121 Internal medicine, 692/163/2743/137/773, NO, Insulin resistance, Internal medicine, Diabetes mellitus, medicine, Mendelian randomization, 631/208/480, Medicinsk genetik, business.industry, General Chemistry, Impaired fasting glucose, business
Abstract

Differences between sexes contribute to variation in the levels of fasting glucose and insulin. Epidemiological studies established a higher prevalence of impaired fasting glucose in men and impaired glucose tolerance in women, however, the genetic component underlying this phenomenon is not established. We assess sex-dimorphic (73,089/50,404 women and 67,506/47,806 men) and sex-combined (151,188/105,056 individuals) fasting glucose/fasting insulin genetic effects via genome-wide association study meta-analyses in individuals of European descent without diabetes. Here we report sex dimorphism in allelic effects on fasting insulin at IRS1 and ZNF12 loci, the latter showing higher RNA expression in whole blood in women compared to men. We also observe sex-homogeneous effects on fasting glucose at seven novel loci. Fasting insulin in women shows stronger genetic correlations than in men with waist-to-hip ratio and anorexia nervosa. Furthermore, waist-to-hip ratio is causally related to insulin resistance in women, but not in men. These results position dissection of metabolic and glycemic health sex dimorphism as a steppingstone for understanding differences in genetic effects between women and men in related phenotypes., Sex differences in fasting glucose and insulin have been identified, but the genetic loci underlying these differences have not. Here, the authors perform a meta-analysis of genome-wide association studies to detect sex-specific and sex-dimorphic loci associated with fasting glucose and insulin.

Published
2021

9. FGF21 in Adipose Tissue Fibrosis, Obesity and Type 2 Diabetes

Author

M Blüher, Rima Chakaroun, A Dietrich, P Kovacs, Lucas Massier, M Patt, S Tabei, Martin Gericke, and T Karlas

Subjects
medicine.medical_specialty, FGF21, Endocrinology, Fibrosis, business.industry, Internal medicine, medicine, Adipose tissue, Type 2 diabetes, medicine.disease, business, Obesity
Published
2021

11. Augmented manipulation ability in humans with six-fingered hands

Author

Michael Mace, M. Blüher, Olaf Blanke, Carsten Mehring, Etienne Burdet, A.-S. Buschhoff, Tobias Pistohl, Luke Bashford, H. Choi, Michel Akselrod, A. Cheah, Andrea Serino, Roy Salomon, and Engineering & Physical Science Research Council (EPSRC)

Subjects
0301 basic medicine, Nervous system, Male, REPRESENTATION, General Physics and Astronomy, 02 engineering and technology, Adolescent, Brain/diagnostic imaging, Brain/physiology, Cerebral Cortex/diagnostic imaging, Cerebral Cortex/physiology, Female, Fingers/diagnostic imaging, Fingers/physiology, Functional Neuroimaging, Hand/diagnostic imaging, Hand/physiology, Humans, Magnetic Resonance Imaging, Middle Aged, Movement/physiology, Muscle, Skeletal/diagnostic imaging, Muscle, Skeletal/physiology, Polydactyly/diagnostic imaging, Polydactyly/physiopathology, Neurotechnology, AREAS, Morphogenesis, lcsh:Science, Cerebral Cortex, Neuromechanics, Multidisciplinary, Polydactyly, Brain, food and beverages, 021001 nanoscience & nanotechnology, Multidisciplinary Sciences, medicine.anatomical_structure, Science & Technology - Other Topics, Motor cortex, 0210 nano-technology, Biomedical engineering, medicine.medical_specialty, Movement, Science, SYNERGIES, General Biochemistry, Genetics and Molecular Biology, Article, Fingers, 03 medical and health sciences, Physical medicine and rehabilitation, Motor control, medicine, Supernumerary, Supernumerary finger, Muscle, Skeletal, Science & Technology, business.industry, fungi, General Chemistry, medicine.disease, Hand, body regions, 030104 developmental biology, lcsh:Q, business
Abstract

Neurotechnology attempts to develop supernumerary limbs, but can the human brain deal with the complexity to control an extra limb and yield advantages from it? Here, we analyzed the neuromechanics and manipulation abilities of two polydactyly subjects who each possess six fingers on their hands. Anatomical MRI of the supernumerary finger (SF) revealed that it is actuated by extra muscles and nerves, and fMRI identified a distinct cortical representation of the SF. In both subjects, the SF was able to move independently from the other fingers. Polydactyly subjects were able to coordinate the SF with their other fingers for more complex movements than five fingered subjects, and so carry out with only one hand tasks normally requiring two hands. These results demonstrate that a body with significantly more degrees-of-freedom can be controlled by the human nervous system without causing motor deficits or impairments and can instead provide superior manipulation abilities., Can the human brain successfully control additional body parts beyond the ones we normally possess? Here, the authors study two polydactyly individuals (with an additional finger on each hand) and show that they can carry out more complex movements, performing with only one hand tasks normally requiring two.

Published
2019

12. Publisher Correction: Sex-dimorphic genetic effects and novel loci for fasting glucose and insulin variability

Author

Stavroula Kanoni, Bakker Sjl., Winkelmann Br, Wieland Kiess, Josée Dupuis, Palmer Cna., James F. Wilson, Schwarz Peh., Maria Dimitriou, Joop Jukema, Sara M. Willems, J L Min, R. Rauramaa, Perry Jrb., Momoko Horikoshi, Timo A. Lakka, Nicole Soranzo, J Kaprio, Niek Verweij, Martina Müller-Nurasyid, Jaana Lindström, Toby Johnson, Olga D. Carlson, Nita G. Forouhi, George Dedoussis, Johnson Pcd., Patrick K.E. Magnusson, Gonçalo R. Abecasis, Ozren Polasek, Wolffenbuttel Bhr., M. I. J. Uusitupa, Longda Jiang, Nancy L. Pedersen, Beate St Pourcain, Erik P A Van Iperen, Iva Miljkovic, Stefania Bandinelli, M. A. Province, Veikko Salomaa, Andrew A. Hicks, Evelin Mihailov, Rick Jansen, James B. Meigs, D Rybin, Peter Kovacs, George Davey Smith, Rona J. Strawbridge, Gudmar Thorleifsson, Meena Kumari, Chiara Scapoli, Christopher J. Groves, Barbara Thorand, T.B. Harris, Ulf de Faire, Inga Prokopenko, Stela McLachlan, Ping An, Anubha Mahajan, L.F. Bielak, Rebecca J. Webster, David Altshuler, Susan Campbell, Bernhard O. Boehm, A. Metspalu, Perttu Salo, D.I. Boomsma, Ilja M. Nolte, Andrea Ganna, Timothy M. Frayling, Pau Navarro, N J Timpson, Kardia Slr., Jeanette M. Stafford, Tõnu Esko, Ulrika Krus, Richa Saxena, Per Eriksson, Peter P. Pramstaller, Anne U. Jackson, V Lagou, Anders Franco-Cereceda, David S. Siscovick, Josephine M. Egan, Loos Rjf., C Gieger, Amanda J. Bennett, Anna Ulrich, Satu Männistö, Mika Kivimäki, Loic Yengo, Caroline Hayward, George Nicholson, C M van Duijn, Anke Tönjes, Nigel W. Rayner, Jose C. Florez, Leif Groop, Valeri Lyssenko, Lyle J. Palmer, Vilmantas Giedraitis, Maria G. Stathopoulou, B. Balkau, Anneli Pouta, Anuj Goel, Pierre Meneton, Serena Sanna, Jesper R. Gådin, Claudia Langenberg, Alessia Faggian, H Grallert, Karen Kapur, Marcus E. Kleber, Philippe Froguel, Boehnke M, Harry Campbell, Anders Hamsten, T. Saaristo, Antigone S. Dimas, Jarvelin M-R., F Karpe, A. Körner, Leena Kinnunen, Markus Perola, Joanne M. Meyer, May E. Montasser, Erik Ingelsson, Naveed Sattar, Yvonne Boettcher, Sirkka Keinänen-Kiukaanniemi, Aaron Isaacs, Gerjan Navis, Ian Ford, Amélie Bonnefond, Reedik Mägi, Tove Fall, Dmitry Shungin, Jenna Price, Igor Rudan, Richard M. Watanabe, Luigi Ferrucci, Jian'an Luan, Harst Pvd., Marika Kaakinen, Tatijana Zemunik, Christian Herder, Shin S-Y., Veronique Vitart, Ross M. Fraser, Alan R. Shuldiner, Panagiotis Deloukas, C. Lecoeur, Letizia Marullo, Kari Stefansson, Lars Lind, Winfried März, L Zudina, Aroon D. Hingorani, Gonneke Willemsen, de Geus Ejcn., Albert V. Smith, Jeffery R. O'Connell, Yongmei Liu, James S. Pankow, Sarah H. Wild, Patricia B. Munroe, Patricia A. Peyser, Nicholas J. Wareham, Tiinamaija Tuomi, Nicholas D. Hastie, Markku Laakso, Albert Hofman, J. Tuomilehto, Emmanouil T. Dermitzakis, Thomas Illig, Tomohiro Tanaka, Cecilia M. Lindgren, Sarin A-P., Alex S. F. Doney, Najaf Amin, Hugh Watkins, Johanna Kuusisto, Andrew P. Morris, Richard N. Bergman, Mark I. McCarthy, Nabila Bouatia-Naji, Günther Silbernagel, João Fadista, Harold Snieder, Ins Barroso, Michael Stumvoll, B.W.J.H. Penninx, M Blüher, Stefan R Bornstein, Laura J. Rasmussen-Torvik, Alan F. Wright, Peter Vollenweider, G K Hovingh, Heikki A. Koistinen, Sophie Visvikis-Siest, Vilmundur Gudnason, Eric Boerwinkle, Hottenga J-J., Guo Li, Paul W. Franks, Université de Lille, Centre de recherche en épidémiologie et santé des populations (CESP), and Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay

Subjects
Genetics, Multidisciplinary, Science, Insulin, medicine.medical_treatment, General Physics and Astronomy, Diagnostic marker, Genome-wide association study, General Chemistry, Type 2 diabetes, Quantitative trait locus, Biology, medicine.disease, GeneralLiterature_MISCELLANEOUS, General Biochemistry, Genetics and Molecular Biology, Fasting glucose, Sexual dimorphism, Pre diabetes, [SDU]Sciences of the Universe [physics], ComputingMethodologies_DOCUMENTANDTEXTPROCESSING, medicine
Abstract

The original version of this Article contained an error in Fig. 2, in which panels a and b were inadvertently swapped. This has now been corrected in the PDF and HTML versions of the Article.

Published
2021

14. Naltrexon/Bupropion in der Adipositastherapie

Author

M. Blüher

Subjects
Gynecology, medicine.medical_specialty, business.industry, medicine, General Medicine, business
Abstract

ZusammenfassungIn der Therapie der Adipositas reichen häufig konservative Basistherapiemaßnahmen wie eine energiereduzierte Mischkost, eine Erhöhung der körperlichen Aktivität sowie eine Verhaltensmodifikation nicht aus, um die individuellen Gesundheitsziele langfristig zu erreichen. Eine medikamentöse Therapie kann bei nicht ausreichendem Erfolg in Kombination mit dem Basisprogramm erwogen werden. Seit Januar 2018 ist mit Naltrexon 32mg/Bupropion 360mg eine neue Pharmakotherapie der Adipositas in Deutschland eingeführt. Naltrexon ist ein _-Opioidrezeptor- Antagonist und Bupropion ein schwacher Inhibitor der neuronalen Dopamin- und Noradrenalin- Wiederaufnahme die zusammen über die Wirkung auf den Nucleus arcuatus des Hypothalamus und das mesolimbische dopaminerge Belohnungssystem zu einer Verringerung der Nahrungsaufnahme beitragen. Die Wirksamkeit und Sicherheit von Naltrexon/Bupropion wurde zusätzlich zur Basistherapie in vier doppelblinden Placebo-kontrollierten Phase III-Studien bei 4 536 Personen mit Adipositas oder Übergewicht über einen Zeitraum von 56 Wochen untersucht (COR-I, COR-II, CORBMOD, COR-Diabetes). Unter Naltrexon/Bupropion wurde in der COR-I Studie eine durchschnittliche prozentuale Gewichtsabnahme von 5,4% im Vergleich zu 1,3% in der Placebogruppe erzielt. Zu den häufigsten Nebenwirkungen von Naltrexon/Bupropion zählen Übelkeit, Erbrechen, Obstipation, Durchfall, Schlaflosigkeit, Kopfschmerzen, Schwindel und Mundtrockenheit.

Published
2018

15. Omega-3-Fettsäuren und Adipositas im Kindes-und Jugendalter

Author

M. Hamm, M. Blüher, V. Richter, and J. Thiery

Abstract

ZusammenfassungEbenso wie bei adipösen Erwachsenen stellt auch bei adipösen Kindern und Jugendlichen eine chronisch-subklinische Entzündung einen Schlüsselfaktor für die Entwicklung von verschiedenen metabolischen Störungen dar. Es wurde gezeigt, dass langkettige Omega-3-Fettsäuren wie Eikosapentaensäure (EPA) und Dokosahexaensäure (DHA) entzündli-chen Prozessen im Fettgewebe entgegenwirken. Die zugrunde liegenden Mechanismen schließen anti-inflammatorische und entzündungsauflösende Effekte dieser Fettsäuren und ihrer bioaktiven Mediatoren ein. Deshalb sind die ausgewogene Zufuhr mehrfach ungesättigter Fettsäuren mit der Nahrung und eine gute Versorgung mit langkettigen Omega-3-Fettsäuren von spezieller Bedeutung.

Published
2017

16. Neurotensin system mediates weight loss response after metabolic surgery

Author

S Tabei, A Tönjes, M Blüher, L Scheffler, Thomas Ebert, Rima Chakaroun, and Michael Stumvoll

Subjects
medicine.medical_specialty, chemistry.chemical_compound, Endocrinology, chemistry, business.industry, Weight loss, Internal medicine, Metabolic surgery, Medicine, medicine.symptom, business, Neurotensin
Published
2019

18. Evidence for bacteria in adipose tissue of morbidly obese patients

Author

Martin Gericke, Henrike O. Heyne, Alyce Crane, M Blüher, Rima Chakaroun, Michael Stumvoll, A Dietrich, S Ziesche, L Scheffler, and P Kovacs

Subjects
medicine.medical_specialty, Endocrinology, biology, business.industry, Internal medicine, medicine, Adipose tissue, Morbidly obese, biology.organism_classification, business, Bacteria
Published
2019

21. Die Klug-entscheiden-Initiative der Deutschen Gesellschaft für Innere Medizin

Author

M. Schott, Martin Reincke, M. Blüher, S. Diederich, Marcus Quinkler, M. Gogol, and J. Feldkamp

Subjects
Gynecology, 03 medical and health sciences, medicine.medical_specialty, 0302 clinical medicine, business.industry, Internal Medicine, Medicine, 030209 endocrinology & metabolism, Hormone replacement therapy, 030204 cardiovascular system & hematology, business
Abstract

A. Nach osteoporosetypischen Frakturen soll bei alteren Patienten in der Regel eine spezifische Osteoporosetherapie eingeleitet werden. a. Osteoporose als Erkrankung des hoheren Lebensalters soll diagnostiziert und behandelt werden (Empfehlung der Deutschen Gesellschaft fur Geriatrie). B. Alle Patienten mit Diabetes mellitus sollen bei Einleitung einer medikamentosen Therapie eine spezifische Schulung erhalten. C. Allen Schwangeren soll eine Jodsupplementation angeboten werden. D. Bei jungeren und therapierefraktaren Patienten soll auch nach endokrinen Ursachen einer Bluthochdruckerkrankung gesucht werden. E. Jede unklare Hyperkalzamie soll abgeklart werden. A. Eine Testosteronsubstitution soll nicht aufgrund eines einzelnen erniedrigten Testosteronwerts ohne Klinik und Ursachenabklarung eingeleitet werden. B. Bildgebende Verfahren sollen erst nach Sicherung einer hormonellen Erkrankung eingesetzt werden. C. Ein Ultraschallscreening auf Schilddrusenveranderungen bei alteren Menschen soll nicht durchgefuhrt werden. D. Eine Dauertherapie mit Levothyroxin bei Struma nodosa soll nicht durchgefuhrt werden. E. Eine Hydrokortisontherapie bei substitutionspflichtigen Patienten soll in relevanten Stresssituationen nicht ohne Dosisanpassung bleiben.

Published
2016

23. Routinemäßige Durchleuchtungsuntersuchungen nach bariatrischen Operationen

Author

A. Ernst, P. Reimer, M.R. Schön, A. Schöttler, K Fedtke, M Blüher, J Jenkner, and D Gärtner

Subjects
Gynecology, medicine.medical_specialty, Sleeve gastrectomy, business.industry, medicine.medical_treatment, 030209 endocrinology & metabolism, 03 medical and health sciences, 0302 clinical medicine, Transplant surgery, Cardiothoracic surgery, medicine, 030211 gastroenterology & hepatology, Surgery, business, Abdominal surgery
Abstract

Klammernaht- oder Anastomoseninsuffizienzen nach bariatrischen Eingriffen stellen fur die Patienten eine ernstzunehmende Komplikation dar. Die Rontgendurchleuchtungsuntersuchung mit oraler Aufnahme eines wasserloslichen Kontrastmittels (DL-U) ist eine Moglichkeit, Insuffizienzen zu diagnostizieren. Ziel dieser Studie ist die Bewertung routinemasiger DL-U nach primaren bariatrischen Eingriffen im Hinblick auf die Detektion postoperativer Komplikationen. Von 01/2009 bis 12/2014 wurden 658 bariatrische Eingriffe durchgefuhrt. 442 Primareingriffe, darunter 307 laparoskopische Sleeve-Gastrektomien (LSG) und 135 laparoskopische Roux-Y-Magenbypasse (LRYGB), wurden in die Studie eingeschlossen. Bis 12/2012 erfolgte eine routinemasige DL-U zwischen dem 1. und 3. postoperativen Tag unabhangig von der klinischen Symptomatik. Die Auswertung der DL-U erfasste die Erkennung von Komplikationen wie Insuffizienzen und Stenosen. Im Untersuchungszeitraum traten 8 Klammernahtinsuffizienzen (2,6 %) nach Sleeve-Gastrektomie auf. Des Weiteren wurden je eine Insuffizienz der Gastrojejunostomie (0,7 %) und eine der Jejunojejunostomie (0,7 %) nach den Magenbypassen diagnostiziert. Alle Patienten wurden durch die klinische Symptomatik auffallig. In einem Fall wurde die Insuffizienz in der Routine-DL-U nachgewiesen, in 9 Fallen war die postoperative Routinerontgendiagnostik unauffallig. Bei keinem Patienten erfolgte ein radiologischer Insuffizienznachweis bei unauffalligem klinischem Befund. Routinemasige, fruhpostoperative DL-U nach bariatrischen Eingriffen sind zur Detektion von Insuffizienzen beim asymptomatischen Patienten nicht geeignet.

Published
2015

24. Das Leipziger Adipositasmanagement

Author

W. Kiess, U. Sass, Mario Hellbardt, M. Blüher, U. Tiesler, R. Striebel, M. Adler, M. Stumvoll, A. Dietrich, A. Hilbert, R. Gausche, M. Fasshauer, and S. V. Schwalm

Subjects
Conservative treatment, Gynecology, medicine.medical_specialty, business.industry, Medicine, General Medicine, business, Follow up care
Abstract

ZusammenfassungDas interdisziplinäre Leipziger Adipositasmanagement ist deutschlandweit das erste Adipositas-Therapieprogramm für Kinder, Jugendliche und Erwachsene, welches durch eine gesetzliche Krankenversicherung (AOK PLUS – Die Gesundheitskasse für Sachsen und Thüringen) mit einem regionalen Versichertenanteil von >50 % finanziert wird. Seit dem 01.08.2014 werden in dem vierjährigen Therapieprogramm sektoren- und fachübergreifend adipöse Menschen in einem modular aufgebauten Behandlungskonzept betreut, nachdem durch eine strukturierte Diagnostik Ein- und Ausschlusskriterien für die verschiedenen Module evaluiert wurden. Innerhalb des Programms werden verschiedene Fachkompetenzen für ein nachhaltiges Gewichtsmanagement in der konservativen sowie chirurgischen Therapie der Adipositas vereint. Das Behandlungskonzept soll die Effizienz der Versorgung verbessern, eine qualitätsgesicherte und evidenzbasierte Therapie sicherstellen und dadurch einen direkten Nutzen für die Patienten erbringen.

Published
2015

28. Insulin oder Chirurgie?

Author

M. Blüher

Subjects
medicine.medical_specialty, business.industry, Disease, Perioperative, Type 2 diabetes, medicine.disease, Obesity, law.invention, Surgery, Randomized controlled trial, law, Weight loss, Diabetes mellitus, medicine, medicine.symptom, business, Dyslipidemia
Abstract

Obesity significantly increases the risk of developing type 2 diabetes by a factor of up to 9. Medical treatment of type 2 diabetes with lifestyle and pharmacological interventions frequently fails to prevent the progress of the disease and the manifestation of diabetes complications. In recent years bariatric metabolic surgery has emerged as an effective treatment for patients with obesity and type 2 diabetes. Compared to medical treatment alone, metabolic surgery has been shown to be more effective in reducing mortality, improving hyperglycemia, hypertension and dyslipidemia in randomized clinical trials among patients with obesity and type 2 diabetes. However, surgery also has the risk for acute perioperative complications, long-term micronutrient deficiencies and psychological problems. Weighing these risks against the benefits of significant weight loss and improved glycemic control, metabolic surgery seems to be a promising treatment option for obesity-associated type 2 diabetes. However, current guidelines and treatment algorithms for the treatment of type 2 diabetes either ignore or underestimate the potential of metabolic surgery. In my opinion, metabolic surgery should be considered earlier in the treatment of type 2 diabetes and obesity and no longer be considered as the last therapeutic option for patients with obesity-associated type 2 diabetes.

Published
2014

29. Das Fettgewebe – ein endokrines Organ

Author

M. Blüher

Subjects
medicine.medical_specialty, business.industry, Insulin, medicine.medical_treatment, media_common.quotation_subject, Adipokine, Adipose tissue, Inflammation, Appetite, medicine.disease, Obesity, Proinflammatory cytokine, Endocrinology, Adipogenesis, Internal medicine, Internal Medicine, medicine, medicine.symptom, business, media_common
Abstract

The incidence of obesity has increased dramatically during recent decades. Obesity increases the risk for metabolic and cardiovascular diseases and may therefore contribute to premature death. With increasing fat mass, secretion of adipose tissue derived bioactive molecules (adipokines) changes towards a proinflammatory, diabetogenic and atherogenic pattern. Adipokines are involved in the regulation of appetite and satiety, energy expenditure, activity, endothelial function, hemostasis, blood pressure, insulin sensitivity, energy metabolism in insulin sensitive tissues, adipogenesis, fat distribution and insulin secretion in pancreatic β-cells. Therefore, adipokines are clinically relevant as biomarkers for fat distribution, adipose tissue function, liver fat content, insulin sensitivity and chronic inflammation and have the potential for future pharmacological treatment strategies for obesity and related diseases. This review focuses on the clinical relevance of selected adipokines as markers or predictors of obesity-related diseases and as potential therapeutic tools or targets in metabolic and cardiovascular diseases.

Published
2014

30. Adipositas und Omega-3-Fettsäuren

Author

U. Ceglarek, M. Hamm, V. Richter, J. Thiery, and M. Blüher

Subjects
Gynecology, medicine.medical_specialty, business.industry, medicine, General Medicine, business
Abstract

ZusammenfassungEine chronische subklinische Entzündung des Fettgewebes, charakterisiert durch ein proinflammatorisches Adipokin-Sekretionsmuster und durch die Infiltration von Entzündungszellen, trägt zu verschiedenen mit der Adipositas verbundenen Stoffwechselstörungen bei. Die langkettigen Omega-3-Fettsäuren Eicosapentaensäure (EPA) und Docosahexaensäure (DHA) wirken inflammatorischen Prozessen im Fettgewebe entgegen, und zwar sowohl auf Stufen der Entwicklung als auch bei der Auflösung der Entzündung. EPA und DHA stellen Substrate für kürzlich identifizierte Familien von entzündungsauflösenden Lipid-Mediatoren dar, speziell von Resolvinen, Protektinen und Maresinen, denen eine wesentliche Rolle in der Begrenzung von Entzündungen zukommt.Als eine Strategie zur Prävention systemischer, mit der Adipositas assoziierter Komplikationen ist es notwendig, die inflammatorischen Prozesse im Fettgewebe günstig zu beeinflussen. Zahlreiche Untersuchungen haben ergeben, dass langkettige Omega-3-Fettsäuren hierzu beitragen und dass die Verfügbarkeit von EPA und DHA das Risiko von Adipositas-assoziierten Stoffwechselerkrankungen verringert. Deshalb ist die Versorgung mit langkettigen Omega-3-Fettsäuren sowohl auf Bevölkerungsebene als auch speziell für adipöse Personen bedeutsam.

Published
2014

31. Evaluation eines zweijährigen strukturierten, ambulanten, bariatrischen Nachsorgeprogramms

Author

M. Blüher, S. V. Schwalm, B. Stöckmann, Mario Hellbardt, B. Schilling-Maßmann, and W. Keuthage

Subjects
Gynecology, medicine.medical_specialty, business.industry, medicine, General Medicine, business
Abstract

ZusammenfassungDie operative Therapie kommt für Patienten mit extremer Adipositas in Frage, wenn mit konservativen Maßnahmen die Therapieziele nicht erreicht werden. Allerdings sind die aktuellen Versorgungsstrukturen sowie eine ungesicherte Finanzierung wesentliche Barrieren für eine adäquate Nachsorge von Patienten nach bariatrischer Operation. In der vorliegenden Arbeit wird der Verlauf einer zweijährigen finanzierten Nachsorge bariatrisch operierter Patienten (n=40) anhand erfasster somatischer Parameter beurteilt. Die Datenerfassung im Rahmes dieser strukturierten Nachsorgeprogramms erfolgte präoperativ und 3, 6, 9, 12, 18 sowie 24 Monate postoperative und wurde mit einer Minimalnachsorge (einmal prä- sowie postoperativ 3. und 18. Monat) verglichen. Neben dem Gewicht wurden Adipositas-assoziierte Krankheiten sowie die Medikation in beiden Nachsorgeregimen deutlich reduziert. Ernährungsabhängige Mangelerscheinungen konnten in der Nachsorge durch gezielte Supplementation sowie regelmäßige Laborkontrollen vorgebeugt werden. Innerhalb der Minimalnachsorge oblag die Kontrolle dem Hausarzt und mögliche Mangelsituationen wurden nicht systematisch erfasst. Eine engmaschige, über zwei Jahre andauernde postoperative Betreuung mit regelmäßigen Laborkontrollen, medizinischen Untersuchungen sowie Diättherapie ist daher empfehlenswert.

Published
2014

33. [Endoscopic treatment of obesity and complications following bariatric surgery]

Author

J, Feisthammel, M, Blüher, J, Mössner, and A, Hoffmeister

Subjects
Reoperation, Evidence-Based Medicine, Postoperative Complications, Technology Assessment, Biomedical, Treatment Outcome, Gastroscopy, Bariatric Surgery, Humans, Minimally Invasive Surgical Procedures, Equipment Design, Obesity, Combined Modality Therapy
Abstract

The prevalence of obesity in the population has been increasing for many years. Due to associated comorbidities the treatment of obesity is becoming more important. Conservative treatment alone is often unsuccessful, particularly in cases of severe obesity. In these cases, multimodal therapy in specialized treatment units is warranted. Between conservative treatment and bariatric surgery, interventional endoscopic treatment options also play an increasing role. Nowadays, implantation of gastric balloons and duodenojejunal bypass liners (EndoBarrier) are the most often used endoscopic options. A further typical application of endoscopy in the treatment of obesity is the management of complications after bariatric surgery, such as stenosis and insufficiency. This article gives an overview on the currently available endoscopic options associated with treatment of obesity.

Published
2016

34. [The Choosing Wisely Initiative of the German Society of Internal Medicine : Recommendations of the German Society for Endocrinology and the German Society for Geriatrics]

Author

J, Feldkamp, M, Schott, M, Gogol, M, Quinkler, M, Blüher, S, Diederich, and M, Reincke

Subjects
Endocrinology, Metabolic Diseases, Geriatrics, Germany, Clinical Decision-Making, Internal Medicine, Humans, Endocrine System Diseases
Abstract

A. After osteoporotic fractures in the elderly, as a rule specific antiosteoporotic therapy should be initiated. a. Osteoporosis as a disease of the elderly should be diagnosed and treated (recommendation of the German Society for Geriatrics). B. All patients with diabetes mellitus should complete a specific diabetes training program when antidiabetic drug medication is initiated. C. In Germany, all pregnant women should be advised to undertake iodine supplementation. D. Endocrine causes of hypertension should be ruled out in younger patients and in patients on multiple antihypertensive drugs. E. All unclear cases of hypercalcemia should be clarified.A. Testosterone substitution therapy should not be initiated on the basis of only one measurement of a reduced testosterone level without clinical signs and clarification of the underlying cause. B. Imaging procedures should only be used after the existence of hormonal disease has been confirmed. C. Sonographic screening for thyroid disease is not advised in the elderly. D. Long-term therapy with levothyroxine for nodular goiter should be avoided. E. In relevant stress situations hydrocortisone replacement therapy should not be continued without dose adjustment in patients with adrenal or pituitary insufficiency.

Published
2016

37. Geschlechtsspezifische Analyse der Inanspruchnahme bariatrischer Chirurgie

Author

S. Dietrich, K. Stengler, and M. Blüher

Subjects
General Medicine
Abstract

Zusammenfassung Hintergrund Adipositas zählt zu den häufigsten Zivilisationskrankheiten mit einer Vielzahl ungünstiger Auswirkungen auf die Gesundheit. Während Frauen und Männer etwa gleiche Lebenszeitprävalenzen haben, ist die Inanspruchnahme bariatrischer Eingriffe unterschiedlich. Ziel der Arbeit ist es, Erklärungsansätze für die Geschlechterunterschiede bei der Inanspruchnahme zusammenzufassen. Methode Literaturrecherche in PubMed. Ergebnisse Mehr Frauen als Männer lassen bariatrische Eingriffe vornehmen. Bei Männern wird die Entscheidung für einen bariatrischen Eingriff vorwiegend durch körperliche Einschränkungen beeinflusst (u.a. Schlafprobleme und Herz-Kreislauferkrankungen). Bei Frauen sind hingegen emotionale Faktoren und psychische Erkrankungen bedeutsam (u.a. depressive Erkrankungen, Essstörungen, verminderte gesundheitsbezogene Lebensqualität sowie Anzahl der Diäten). DiskussionDa bisher nur wenige geschlechtsspezifische Daten zu bariatrischen Eingriffen vorliegen, sind weitere Studien zu geschlechtsspezifischen Zusammenhängen im Vorfeld und bei der Inanspruchnahme bariatrischer Eingriffe bei größeren Patientenkollektiven notwendig, die generalisierbare, repräsentative Aussagen zulassen.

Published
2012

40. Adipositaschirurgie bei morbid adipösen

Author

M. Stumvoll, C. Rohde, O. Münsterer, Wieland Kiess, H. Till, M. Blüher, S. Blüher, C. Beckert-Zieglschmid, and K. von Klitzing

Subjects
General Medicine
Abstract

ZusammenfassungVerfahren der Adipositaschirurgie stellen eine Therapieoption dar bei extrem adipösen Erwachsenen und zunehmend auch bei Jugendlichen mit morbider Adipositas, bei denen die konservativen Therapieansätze (Ernährungsanalyse und -schulung, Steigerung der körperlichen Aktivität, psychologische und familientherapeutische Intervention) nicht zum gewünschten Erfolg geführt haben. Die wenigen bisher zur Verfügung stehenden Daten zur Adipositaschirurgie im Jugendalter berichten nicht nur über eine signifikante postoperative BMI-Reduktion, sondern zeigen auch eine deutliche Verbesserung von präoperativ bereits bestehenden Begleiterkrankungen und dem psychosozialen Wohlbefinden. Die Indikationsstellung zur Adipositaschirurgie sowie obligate präoperative Untersuchungen sollten in speziellen Adipositas-Zentren erfolgen. Für die prä- und postoperative Betreuung ist ein interdisziplinäres Team bestehend aus Pädiater/Internist, (Kinder-)Chirurg, Anästhesist, (Kinder-)Psychiater bzw. -psychologe und Ökotrophologe wünschenswert.

Published
2008

41. [Routine fluoroscopic investigations after primary bariatric surgery]

Author

D, Gärtner, A, Ernst, K, Fedtke, J, Jenkner, A, Schöttler, P, Reimer, M, Blüher, and M R, Schön

Subjects
Adult, Male, Gastroplasty, Gastric Bypass, Bariatric Surgery, Anastomosis, Roux-en-Y, Anastomotic Leak, Middle Aged, Postoperative Complications, Surgical Staplers, Fluoroscopy, Surgical Wound Dehiscence, Humans, Female, Laparoscopy
Abstract

Staple line and anastomotic leakages are life-threatening complications after bariatric surgery. Upper gastrointestinal (GI) tract X-ray examination with oral administration of a water-soluble contrast agent can be used to detect leaks. The aim of this study was to evaluate the impact of routine upper GI tract fluoroscopy after primary bariatric surgery.Between January 2009 and December 2014 a total of 658 bariatric interventions were carried out of which 442 were primary bariatric operations. Included in this single center study were 307 sleeve gastrectomies and 135 Roux-en-Y gastric bypasses. Up to December 2012 upper GI tract fluoroscopy was performed routinely between the first and third postoperative days and the detection of leakages was evaluated.In the investigation period 8 leakages (2.6 %) after sleeve gastrectomy, 1 anastomotic leakage in gastrojejunostomy and 1 in jejunojejunostomy after Roux-en-Y gastric bypass occurred. All patients developed clinical symptoms, such as abdominal pain, tachycardia or fever. In one case the leakage was detected by upper GI fluoroscopy and in nine cases radiological findings were unremarkable. No leakages were detected in asymptomatic patients.Routine upper GI fluoroscopy is not recommended for uneventful postoperative courses after primary bariatric surgery.

Published
2015

44. [Pharmacological therapy versus bariatric surgery for patients with obesity and type 2 diabetes]

Author

M, Blüher

Subjects
Evidence-Based Medicine, Treatment Outcome, Diabetes Mellitus, Type 2, Bariatric Surgery, Humans, Hypoglycemic Agents, Obesity, Combined Modality Therapy
Abstract

There is strong epidemiological evidence for an association between increased body weight and a higher incidence of type 2 diabetes. Moreover, reduction in body weight may delay the onset of type 2 diabetes. The basic therapy of type 2 diabetes includes lifestyle modifications, such as education, nutritional advice, increased physical activity, non-smoking and strategies to cope with stress. If lifestyle modifications are not successful, antidiabetic pharmacotherapy is stepwise intensified to achieve individual therapeutic targets; however, pharmacological treatment of type 2 diabetes frequently fails to prevent the progress of the disease and the manifestation of diabetes complications. Sustained weight reduction belongs to the individual treatment targets for patients with obesity and type 2 diabetes. Because conservative weight reduction strategies are frequently not successful, bariatric surgery has emerged as an effective treatment particularly for those patients with obesity-associated type 2 diabetes in whom a glycosylated hemoglobin (HbA1c) target 7.5% could not be achieved with pharmacological therapy. Bariatric surgery should no longer be considered as the last option for patients with obesity-associated type 2 diabetes.

Published
2015

45. Das metabolische Syndrom - Mythen, Mechanismen, Management

Author

M Stumvoll and M Blüher

Subjects
medicine.medical_specialty, business.industry, Diabetes mellitus, Internal medicine, Cardiovascular risk factors, medicine, General Medicine, Metabolic syndrome, medicine.disease, business, Obesity, Syndrome x
Published
2006

46. [Insulin or surgery? : the perspective of a diabetologist]

Author

M, Blüher

Subjects
Postoperative Complications, Diabetes Mellitus, Type 2, Bariatric Surgery, Humans, Hypoglycemic Agents, Insulin, Obesity, Morbid, Randomized Controlled Trials as Topic
Abstract

Obesity significantly increases the risk of developing type 2 diabetes by a factor of up to 9. Medical treatment of type 2 diabetes with lifestyle and pharmacological interventions frequently fails to prevent the progress of the disease and the manifestation of diabetes complications. In recent years bariatric metabolic surgery has emerged as an effective treatment for patients with obesity and type 2 diabetes. Compared to medical treatment alone, metabolic surgery has been shown to be more effective in reducing mortality, improving hyperglycemia, hypertension and dyslipidemia in randomized clinical trials among patients with obesity and type 2 diabetes. However, surgery also has the risk for acute perioperative complications, long-term micronutrient deficiencies and psychological problems. Weighing these risks against the benefits of significant weight loss and improved glycemic control, metabolic surgery seems to be a promising treatment option for obesity-associated type 2 diabetes. However, current guidelines and treatment algorithms for the treatment of type 2 diabetes either ignore or underestimate the potential of metabolic surgery. In my opinion, metabolic surgery should be considered earlier in the treatment of type 2 diabetes and obesity and no longer be considered as the last therapeutic option for patients with obesity-associated type 2 diabetes.

Published
2014

48. [Adipose tissue--an endocrine organ]

Author

M, Blüher

Subjects
Adipokines, Adipose Tissue, Models, Immunological, Animals, Humans, Endocrine System, Obesity
Abstract

The incidence of obesity has increased dramatically during recent decades. Obesity increases the risk for metabolic and cardiovascular diseases and may therefore contribute to premature death. With increasing fat mass, secretion of adipose tissue derived bioactive molecules (adipokines) changes towards a proinflammatory, diabetogenic and atherogenic pattern. Adipokines are involved in the regulation of appetite and satiety, energy expenditure, activity, endothelial function, hemostasis, blood pressure, insulin sensitivity, energy metabolism in insulin sensitive tissues, adipogenesis, fat distribution and insulin secretion in pancreatic β-cells. Therefore, adipokines are clinically relevant as biomarkers for fat distribution, adipose tissue function, liver fat content, insulin sensitivity and chronic inflammation and have the potential for future pharmacological treatment strategies for obesity and related diseases. This review focuses on the clinical relevance of selected adipokines as markers or predictors of obesity-related diseases and as potential therapeutic tools or targets in metabolic and cardiovascular diseases.

Published
2014

50. Besondere Situationen bei Diabetes mellitus

Author

D. Kopf, K. Müssig, M. Blüher, M. Ehren, W. Druml, M. Pfohl, M. Hummel, and E. Schifferdecker

Abstract

Das Coma diabeticum, die hyperglykamische Entgleisung, war bis zur Einfuhrung der Insulin therapie im Jahre 1922/23 die unabwendbare Todesursache fur nahezu alle Patienten mit Typ-1- und auch viele mit Typ-2-Diabetes.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results